PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
3.04
P/E exceeding 1.5x Medical - Pharmaceuticals median of 1.67. Michael Burry would check for market euphoria. Scrutinize growth expectations.
0.29
P/S less than half the Medical - Pharmaceuticals median of 6.45. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.71
P/B less than half the Medical - Pharmaceuticals median of 1.70. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
2.50
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
2.15
P/OCF of 2.15 versus zero operating cash flow in Medical - Pharmaceuticals. Walter Schloss would verify operational quality.
0.71
Fair value ratio less than half the Medical - Pharmaceuticals median of 1.70. Joel Greenblatt would investigate if this discount is justified.
8.22%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.51%. Joel Greenblatt would investigate if high yield reflects hidden value.
40.02%
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash generation advantage.